Free Trial

Vivani Medical (VANI) Competitors

Vivani Medical logo
$1.29
-0.02 (-1.53%)
(As of 11/1/2024 ET)

VANI vs. ZYXI, RCEL, SGHT, LUNG, SMLR, NVRO, SKIN, ELMD, NPCE, and PROF

Should you be buying Vivani Medical stock or one of its competitors? The main competitors of Vivani Medical include Zynex (ZYXI), AVITA Medical (RCEL), Sight Sciences (SGHT), Pulmonx (LUNG), Semler Scientific (SMLR), Nevro (NVRO), Beauty Health (SKIN), Electromed (ELMD), NeuroPace (NPCE), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry.

Vivani Medical vs.

Vivani Medical (NASDAQ:VANI) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.

Vivani Medical has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Zynex has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vivani MedicalN/AN/A-$25.65M-$0.47-2.74
Zynex$184.32M1.51$9.73M$0.1558.40

In the previous week, Zynex had 8 more articles in the media than Vivani Medical. MarketBeat recorded 8 mentions for Zynex and 0 mentions for Vivani Medical. Zynex's average media sentiment score of 0.10 beat Vivani Medical's score of 0.00 indicating that Zynex is being referred to more favorably in the news media.

Company Overall Sentiment
Vivani Medical Neutral
Zynex Neutral

Zynex has a consensus price target of $14.00, indicating a potential upside of 59.82%. Given Zynex's higher probable upside, analysts plainly believe Zynex is more favorable than Vivani Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vivani Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Zynex
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Zynex received 27 more outperform votes than Vivani Medical when rated by MarketBeat users. However, 100.00% of users gave Vivani Medical an outperform vote while only 57.14% of users gave Zynex an outperform vote.

CompanyUnderperformOutperform
Vivani MedicalOutperform Votes
1
100.00%
Underperform Votes
No Votes
ZynexOutperform Votes
28
57.14%
Underperform Votes
21
42.86%

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 44.3% of Vivani Medical shares are owned by company insiders. Comparatively, 52.1% of Zynex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Zynex has a net margin of 2.49% compared to Vivani Medical's net margin of 0.00%. Zynex's return on equity of 13.05% beat Vivani Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Vivani MedicalN/A -97.30% -48.13%
Zynex 2.49%13.05%3.78%

Summary

Zynex beats Vivani Medical on 14 of the 16 factors compared between the two stocks.

Get Vivani Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for VANI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VANI vs. The Competition

MetricVivani MedicalElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$71.29M$3.57B$5.40B$8.53B
Dividend YieldN/A1.61%5.15%4.14%
P/E Ratio-2.7416.11113.7615.14
Price / SalesN/A56.391,483.0493.53
Price / CashN/A46.0939.7134.04
Price / Book3.153.504.665.01
Net Income-$25.65M$89.83M$119.06M$225.46M
7 Day Performance2.38%1.00%0.79%0.37%
1 Month Performance12.17%14.23%5.65%3.57%
1 Year Performance24.04%17.99%36.80%29.42%

Vivani Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VANI
Vivani Medical
N/A$1.29
-1.5%
N/A+22.8%$71.29MN/A-2.7420
ZYXI
Zynex
3.7459 of 5 stars
$8.76
+1.5%
$14.00
+59.8%
-1.5%$279.01M$184.32M58.401,100Gap Down
RCEL
AVITA Medical
1.1347 of 5 stars
$10.30
+2.0%
$15.00
+45.6%
+5.6%$267.70M$54.14M-5.28130Upcoming Earnings
News Coverage
SGHT
Sight Sciences
2.5214 of 5 stars
$5.21
+4.2%
$7.25
+39.2%
+229.7%$262.12M$81.06M-4.87210Upcoming Earnings
LUNG
Pulmonx
2.6535 of 5 stars
$6.27
+0.3%
$14.67
+133.9%
-30.9%$245.47M$68.68M-4.27250Analyst Forecast
News Coverage
SMLR
Semler Scientific
1.463 of 5 stars
$30.68
+4.4%
N/A+7.2%$214.52M$61.74M15.0492Upcoming Earnings
NVRO
Nevro
2.5874 of 5 stars
$5.53
+0.4%
$9.80
+77.2%
-62.0%$206.18M$426.10M-2.601,215Analyst Upgrade
SKIN
Beauty Health
2.9254 of 5 stars
$1.66
+2.5%
$2.46
+48.1%
-58.1%$205.87M$398M-2.001,030
ELMD
Electromed
N/A$22.90
-1.5%
N/A+118.9%$192.36M$54.72M39.48174
NPCE
NeuroPace
3.3071 of 5 stars
$6.29
-2.5%
$14.00
+122.6%
-8.8%$183.67M$65.42M-5.77170
PROF
Profound Medical
2.172 of 5 stars
$7.35
+1.1%
$13.75
+87.1%
-13.3%$179.29M$7.20M-6.02150Upcoming Earnings
News Coverage

Related Companies and Tools


This page (NASDAQ:VANI) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners